Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907152034> ?p ?o ?g. }
- W2907152034 endingPage "e0210188" @default.
- W2907152034 startingPage "e0210188" @default.
- W2907152034 abstract "Recent evidence indicates that AZD8999 (LAS190792), a novel muscarinic acetylcholine receptor antagonist and β2-adrenoceptor agonist (MABA) in development for chronic respiratory diseases, induces potent and sustained relaxant effects in human bronchi by adressing both muscarinic acetylcholine receptors and β2-adrenoceptor. However, the anti-inflammatory effects of the AZD8999 monotherapy or in combination with corticosteroids are unknown. This study investigates the anti-inflammatory effects of AZD8999 in monotherapy and combined with fluticasone propionate in neutrophils from healthy and chronic obstructive pulmonary disease (COPD) patients. Peripheral blood neutrophils from healthy and COPD patients were incubated with AZD8999 and fluticasone propionate, individually or in combination, for 1h followed by lipopolysaccharide (LPS) stimulation for 6h. The IL-8, MMP9, IL-1β, and GM-CSF release was measured in cell culture supernatants. AZD8999 shows ~ 50% maximum inhibitory effect and similar potency inhibiting the released cytokines in neutrophils from healthy and COPD patients. However, while fluticasone propionate suppresses mediator release in neutrophils from healthy patients, COPD neutrophils are less sensitive. The combination of non-effective concentrations of AZD8999 (0.01nM) with non-effective concentrations of fluticasone propionate (0.1nM) shows synergistic anti-inflammatory effects. The studied mechanisms that may be involved in the synergistic anti-inflammatory effects of this combination include the increase of glucocorticoid receptor (GR)α and MKP1 expression, the induction of glucocorticoid response element (GRE) activation and the decrease of ERK1/2, P38 and GR-Ser226 phosphorylations compared with monotherapies. In summary, AZD8999 shows anti-inflammatory effects in neutrophils from COPD patients and induces synergistic anti-inflammatory effects when combined with fluticasone propionate, supporting the use of MABA/ICS combination therapy in COPD." @default.
- W2907152034 created "2019-01-11" @default.
- W2907152034 creator A5003086206 @default.
- W2907152034 creator A5011244775 @default.
- W2907152034 creator A5021858739 @default.
- W2907152034 creator A5027886817 @default.
- W2907152034 creator A5048155542 @default.
- W2907152034 creator A5058126569 @default.
- W2907152034 creator A5078648343 @default.
- W2907152034 creator A5041074842 @default.
- W2907152034 date "2019-01-04" @default.
- W2907152034 modified "2023-10-15" @default.
- W2907152034 title "In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients" @default.
- W2907152034 cites W1598054520 @default.
- W2907152034 cites W1966678873 @default.
- W2907152034 cites W1969804317 @default.
- W2907152034 cites W1974904073 @default.
- W2907152034 cites W1978775652 @default.
- W2907152034 cites W1980105210 @default.
- W2907152034 cites W1985714596 @default.
- W2907152034 cites W1988682232 @default.
- W2907152034 cites W1989016734 @default.
- W2907152034 cites W1991119065 @default.
- W2907152034 cites W1991529775 @default.
- W2907152034 cites W1992308009 @default.
- W2907152034 cites W1998900781 @default.
- W2907152034 cites W2046386101 @default.
- W2907152034 cites W2065764124 @default.
- W2907152034 cites W2084632288 @default.
- W2907152034 cites W2089664288 @default.
- W2907152034 cites W2101978351 @default.
- W2907152034 cites W2120759924 @default.
- W2907152034 cites W2127538406 @default.
- W2907152034 cites W2127938597 @default.
- W2907152034 cites W2127951128 @default.
- W2907152034 cites W2149362097 @default.
- W2907152034 cites W2168899072 @default.
- W2907152034 cites W2177915374 @default.
- W2907152034 cites W2365138737 @default.
- W2907152034 cites W2401306489 @default.
- W2907152034 cites W2555920109 @default.
- W2907152034 cites W2604775613 @default.
- W2907152034 cites W2734494884 @default.
- W2907152034 cites W2784033289 @default.
- W2907152034 cites W2901739492 @default.
- W2907152034 cites W4245234683 @default.
- W2907152034 doi "https://doi.org/10.1371/journal.pone.0210188" @default.
- W2907152034 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6319735" @default.
- W2907152034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30608978" @default.
- W2907152034 hasPublicationYear "2019" @default.
- W2907152034 type Work @default.
- W2907152034 sameAs 2907152034 @default.
- W2907152034 citedByCount "9" @default.
- W2907152034 countsByYear W29071520342019 @default.
- W2907152034 countsByYear W29071520342020 @default.
- W2907152034 countsByYear W29071520342021 @default.
- W2907152034 countsByYear W29071520342022 @default.
- W2907152034 countsByYear W29071520342023 @default.
- W2907152034 crossrefType "journal-article" @default.
- W2907152034 hasAuthorship W2907152034A5003086206 @default.
- W2907152034 hasAuthorship W2907152034A5011244775 @default.
- W2907152034 hasAuthorship W2907152034A5021858739 @default.
- W2907152034 hasAuthorship W2907152034A5027886817 @default.
- W2907152034 hasAuthorship W2907152034A5041074842 @default.
- W2907152034 hasAuthorship W2907152034A5048155542 @default.
- W2907152034 hasAuthorship W2907152034A5058126569 @default.
- W2907152034 hasAuthorship W2907152034A5078648343 @default.
- W2907152034 hasBestOaLocation W29071520341 @default.
- W2907152034 hasConcept C126322002 @default.
- W2907152034 hasConcept C134018914 @default.
- W2907152034 hasConcept C170493617 @default.
- W2907152034 hasConcept C185592680 @default.
- W2907152034 hasConcept C2776723954 @default.
- W2907152034 hasConcept C2776780178 @default.
- W2907152034 hasConcept C2776804153 @default.
- W2907152034 hasConcept C2778938600 @default.
- W2907152034 hasConcept C2779028295 @default.
- W2907152034 hasConcept C2781212218 @default.
- W2907152034 hasConcept C33789571 @default.
- W2907152034 hasConcept C71924100 @default.
- W2907152034 hasConcept C98274493 @default.
- W2907152034 hasConceptScore W2907152034C126322002 @default.
- W2907152034 hasConceptScore W2907152034C134018914 @default.
- W2907152034 hasConceptScore W2907152034C170493617 @default.
- W2907152034 hasConceptScore W2907152034C185592680 @default.
- W2907152034 hasConceptScore W2907152034C2776723954 @default.
- W2907152034 hasConceptScore W2907152034C2776780178 @default.
- W2907152034 hasConceptScore W2907152034C2776804153 @default.
- W2907152034 hasConceptScore W2907152034C2778938600 @default.
- W2907152034 hasConceptScore W2907152034C2779028295 @default.
- W2907152034 hasConceptScore W2907152034C2781212218 @default.
- W2907152034 hasConceptScore W2907152034C33789571 @default.
- W2907152034 hasConceptScore W2907152034C71924100 @default.
- W2907152034 hasConceptScore W2907152034C98274493 @default.
- W2907152034 hasFunder F4320321837 @default.
- W2907152034 hasFunder F4320321864 @default.
- W2907152034 hasFunder F4320334923 @default.
- W2907152034 hasIssue "1" @default.